News & Events
News & Events
Institut Pasteur Korea Advances Cooperation with POSTECH-Affiliated Research Institutes for Vaccine and Treatment Development
2025-01-02
Institut Pasteur Korea Advances Cooperation with
POSTECH-Affiliated Research Institutes for
Vaccine and Treatment Development
Vaccine and Treatment Development
- Promote Joint Research on mRNA Vaccine and Treatment Development
and Next-Generation Platforms –
- Signed MOU with Four Organizations, Including the Cell Membrane Protein Research Institute -
- Signed MOU with Four Organizations, Including the Cell Membrane Protein Research Institute -
(Dec, 20, 2024, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) signed a memorandum of understanding (MOU) with four organizations under Pohang University of Science and Technology (POSTECH), including the Institute of Membrane Proteins (IMP), Innovation Research Center for Bio-furure Technology (BIRC), Global Exosome Research Institute, and Microbiome Core Research Support Center. The parties would pursue joint research on mRNA vaccine and treatment development.
The MOU was signed at the Institute of Membrane Proteins on the 19th. During the joint research seminar held after the signing ceremony, each institution introduced its key research areas and discussed potential research collaboration.
This agreement was initiated to develop effective mRNA vaccines and treatments, as well as to build next-generation platform technologies in preparation for and response to (re)emerging infectious diseases. The institutions plan to explore research exchanges, foster mutual cooperation, and collaborate in the joint use of research facilities and equipment. Additionally, they aim to develop cooperation models for large-scale national research projects and establish an open lab for research collaboration.
The agreement is expected to promote joint research and the use of cutting-edge equipment for structure-based new drug development and the discovery of new drug candidate. Each institution will drive research and development of mRNA vaccines and treatment, leveraging expertise in areas such as gene and cell therapy, exosomes, and microbiomes, as well as equipment like Cryo-EM (Cryogenic Electron Microscopy) and antibody development facilities.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “Building on IPK’s research into mRNA vaccines and treatments, we aim to strengthen collaboration with POSTECH’s research institutes, which boast exceptional research capabilities and state-of-the-art infrastructure.”